Here are the 10-Q quarterly reports from Vitanova Life Sciences (VNOV) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VNOV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VNOV filings page.
VitaNova Life Sciences Corporation (VNOV) reported a sharp revenue increase but lower profitability for the quarter ended July 31, 2026. Revenue rose to $321,576 from $103,899 a year earlier, driven mainly by the new healthy food products line, which contributed $234,576 of sales.
Despite higher sales, gross profit fell to $30,521 from $68,781 and gross margin dropped to 9% from 66%, as food products carried only about a 3% margin and dietary supplement sales declined. Net loss widened to $123,101 from $46,301, and cash from operating activities decreased to $6,965 from $263,811.
The company ended the quarter with $1,604,182 in cash, total assets of $2,239,335, and total liabilities of $311,656, with no preferred stock outstanding and 8,337,454 common shares issued and outstanding. Management identified material weaknesses in internal control, including the absence of an audit committee and insufficient qualified accounting personnel, though it believes current cash and operating cash flows will cover working capital needs for the next 12 months.
VitaNova Life Sciences Corporation reported sharply higher sales but moved into a small loss for the quarter and nine months ended January 31, 2026. Revenue reached $709,625 for the quarter and $1,240,639 for nine months, increases of 130% and 75% driven by its dietary supplement segment. Gross profit rose, but margins narrowed as cost of revenue grew faster than sales and general and administrative expenses climbed to $405,339 for nine months, largely from higher legal and professional fees. The company posted net losses of $44,362 for the quarter and $54,853 year‑to‑date, compared with profits a year earlier, and recorded an effective tax rate above the statutory level. Cash improved to $1,168,904 with operating cash flow of $386,094, and shareholders’ equity was $1,853,831 with 8,337,454 common shares outstanding as of March 11, 2026. Management highlights continued material weaknesses in internal controls and a high dependence on a few customers and a single vendor, while also noting a recent name change, a 1‑for‑3 reverse stock split, and formation of a new wholly owned subsidiary, VitaNova Global Foods Corporation.